GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
This is the first drug to receive a recommendation for this preventative indication in the European Union
The antibody was designed and developed at Abzena’s Cambridge, UK,
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Subscribe To Our Newsletter & Stay Updated
